Valneva SE (VALN) stock
Close on Nov 12, 2026Market cap $499.79MP/E –Yield –
Valneva SE saw revenue fall 27.2% to €142.94M over the twelve months to Jun 30, 2026. Free cash flow was -€58.04M. At the latest close the market valued the company at €448.09M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- €448.09M
- P/E ratio
- –
- Price to sales
- 3.13
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -12.95%
Fundamentals
- Revenue
- €142.94M
- EPS, diluted
- -0.68 EUR
- Free cash flow
- -€58.04M
Trading
- Previous close
- $5.92
- Open
- $5.91
- Day's range
- $5.73 – $5.91
- Volume
- 5,549
- Average volume (20 days)
- 19,039
- Beta (5 years)
- 1.68
- RSI (14 days)
- 55.5
- Volatility (1 year)
- 66.4%
- Relative volume
- 0.83×
- WACC
- 12.8%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | VALN | S&P 500 | Difference | VALN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.9% | -2.7% | −0.2 pts | ||
| 3 months | +3.8% | -1.7% | +5.5 pts | ||
| Year to date | -34.7% | +11.9% | −46.6 pts | ||
| 1 year | -37.3% | +12.0% | −49.3 pts | ||
| 3 years | -58.3% | +78.2% | −136.5 pts | -25.3% | +21.2% |
| 5 years | -88.0% | +73.2% | −161.3 pts | -34.6% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, EUR
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Valneva filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Valneva
Biological Products, (No Diagnostic Substances)
Valneva SE is a specialty vaccine company that discovers, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with significant unmet medical needs. The company's commercialized product portfolio features travel vaccines, including IXIARO for the prevention of Japanese encephalitis, DUKORAL for cholera and traveler's diarrhea caused by LT-ETEC, and IXCHIQ for chikungunya. Valneva serves travelers, military personnel, and global populations vulnerable to endemic infectious threats. Additionally, it advances late-stage clinical candidates, such as a Lyme disease vaccine developed in partnership with Pfizer and a tetravalent Shigella vaccine candidate.
Company profile, executives and historyValneva stock: common questions
What is Valneva's stock price?
VALN closed at $5.76 on Nov 12, 2026, down 2.70% on the day.
What is Valneva's market cap?
Valneva was worth $499.79M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is VALN's P/E ratio?
Valneva lost money over fiscal 2025 (diluted EPS -0.68 EUR), so it has no meaningful P/E ratio.
How much revenue does Valneva make?
Valneva reported revenue of €142.94M for the twelve months to Jun 30, 2026, down 27.2% from a year earlier.
Does Valneva pay a dividend?
No. Valneva has not paid a cash dividend over the last twelve months.
How has VALN stock performed over the past year?
Including dividends, VALN returned -37.3% over the past year, against +12.0% for the S&P 500.
Who are Valneva's competitors?
Companies most similar to Valneva by business, industry and size include VXRT, NVAX, AGEN, IVVD, VIR.
See a number that looks wrong?